People whose blood pressure is hard to control might have another condition that’s the real culprit. So why aren’t they being tested for primary aldosteronism?

Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.

New findings give reason to pay attention to metabolic dysfunction well before middle age.

New study finds medical namesakes are losing their prominence in neurology, replaced by increasing reliance on clear, descriptive labels.

Researchers report the ability to improve safety and efficacy using a CRISPR-Cas9 variant known as miCas9.

Basic science research explores the effects of impaired glycine metabolism in nonalcoholic fatty liver disease and how to potentially use glycine-based treatment to help people with NAFLD.